# US 11,110,053 B2 · Compositions and methods for the prevention and treatment of cardiovascular diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,110,053 B2
- Document ID: US11110053B2
- Status: Granted
- Kind: B2
- Application number: 15/692,694
- Filed: 2017-08-31
- Published: 2017-12-21
- Granted: 2021-09-07
- Earliest claimed: 2008-07-25
- Assignees: Reven Pharmaceuticals, Inc.
- Applicants: Reven Pharmaceuticals Inc.
- Inventors: Henk Van Wyk; Mariette Van Wyk; Trace Krebs; Peter Lange; Brian Denomme; Michael A. Volk
- Web page: https://patentgrep.com/patent/US11110053B2

## CPC

- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 31/16: Amides, e.g. hydroxamic acids
- A61K 31/167: having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
- A61K 31/341: not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
- A61K 31/375: Ascorbic acid, i.e. vitamin C; Salts thereof
- A61K 31/4415: Pyridoxine, i.e. Vitamin B6 (pyridoxal phosphate A61K31/675)
- A61K 31/455: Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
- A61K 31/51: Thiamines, e.g. vitamin B1
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/525: Isoalloxazines, e.g. riboflavins, vitamin B2
- A61K 31/555: containing heavy metals, e.g. hemin, hematin, melarsoprol
- A61K 31/675: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A61K 31/714: Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
- A61K 33/00: Medicinal preparations containing inorganic active ingredients
- A61K 33/06: Aluminium, calcium or magnesium; Compounds thereof {, e.g. clay}
- A61K 33/14: Alkali metal chlorides; Alkaline earth metal chlorides
- A61K 41/0047: {Sonopheresis, i.e. ultrasonically-enhanced transdermal delivery, electroporation of a pharmacologically active agent}
- A61P 3/06: Antihyperlipidemics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/12: Antihypertensives
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Compositions comprising electro-activated aqueous solutions and methods for the prevention and treatment of dysfunctional cardiovascular conditions are provided.

## Claims

### Claim 1

A therapeutic composition consisting of:
an electro-activated solution with a stable negative oxidation-reduction potential in a range between 50 mV and 500 mV, a conductivity between 11 and 15 mS/cm and a pH in the range between 6.5 and 7.6, the electro-activated solution consisting of:
0.5-10% magnesium sulfate hexahydrate;
5.0-20% ascorbic acid;
0.2-2.0% niacinamide;
0.2-2% pyridoxin HCl;
0.01-2.0% calcium D pantothenate;
0.1-1.0% thiamin HCl;
0.01-0.1% riboflavin;
0.001-0.1% cyanocobalamin;
0.5-10% sodium bicarbonate; 0.8-1% sodium chloride; and electrochemically activated water.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the magnesium sulfate hexahydrate is at 0.05-0.075%.

### Claim 3

A therapeutic composition consisting of the product of a method of preparing a therapeutic composition with a stable negative oxidation-reduction potential in a range between −50 mV and −900 mV, a conductivity between 11 and 15 mS/cm and a pH in the range between 6.5 and 7.6, the method comprising:
mixing a first electroactivated solution with a second electroactivated solution, the first electroactivated solution having a stable negative oxidation-reduction potential and the second electroactivated solution having a stable positive oxication oxidation-reduction potential, wherein
the first electroactivated solution has an oxidation-reduction potential in the range between −500 mV and −900 mV for a period of at least 12 months and a pH in the range between 3.2 and 4.5, and one liter of the first electroactivated solution consists of: 83.6-95.5 g/L ascorbic acid; 57.1-64.7 g/L magnesium sulfate hexahydrate; 9.4-10.6 g/L niacinamide; 9.4-10.6 g/L pyridoxin HCl; 0.18-0.29 g/L riboflavin-5-phosphate sodium; 5.75-6.5 g/L thiamin HCl; 0.17-0.2 g/L cyanocobalamin crystalline; and electrochemically activated water,
the second electroactivated solution has an oxidation-reduction potential in the range between +500 mV and +900 mV for a period of at least 12 months and a pH in the range between 6.5 and 7.8, and one liter of the second electroactivated solution consists of: 82.4-93.2 g/L sodium bicarbonate USP, 19.1-21.8 g/L magnesium sulfate hexahydrate; and electrochemically activated water,
and the step of mixing comprises mixing equal volumes of the first electroactivated solution and the second electroactivated solution.